{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:04Z","timestamp":1792788904832,"version":"4.5.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N011775\/1"],"award-info":[{"award-number":["MR\/N011775\/1"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["IS-BRC-1215-20015"],"award-info":[{"award-number":["IS-BRC-1215-20015"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["IS-BRC-1215-20015"],"award-info":[{"award-number":["IS-BRC-1215-20015"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["MIC-2016-015"],"award-info":[{"award-number":["MIC-2016-015"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucocorticoids are widely used to reduce disease activity and inflammation in patients with a range of immune-mediated inflammatory diseases. It is uncertain whether or not low to moderate glucocorticoid dose increases cardiovascular risk. We aimed to quantify glucocorticoid dose-dependent cardiovascular risk in people with 6 immune-mediated inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a population-based cohort analysis of medical records from 389 primary care practices contributing data to the United Kingdom Clinical Practice Research Datalink (CPRD), linked to hospital admissions and deaths in 1998\u20132017. We estimated time-variant daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard ratios (HRs) of first all-cause and type-specific cardiovascular diseases (CVDs). There were 87,794 patients with giant cell arteritis and\/or polymyalgia rheumatica (\n                      <jats:italic>n<\/jats:italic>\n                      = 25,581), inflammatory bowel disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 27,739), rheumatoid arthritis (\n                      <jats:italic>n<\/jats:italic>\n                      = 25,324), systemic lupus erythematosus (\n                      <jats:italic>n<\/jats:italic>\n                      = 3,951), and\/or vasculitis (\n                      <jats:italic>n<\/jats:italic>\n                      = 5,199), and no prior CVD. Mean age was 56 years and 34.1% were men. The median follow-up time was 5.0 years, and the proportions of person\u2013years spent at each level of glucocorticoid daily exposure were 80% for non-use, 6.0% for &lt;5 mg, 11.2% for 5.0\u201314.9 mg, 1.6% for 15.0\u201324.9 mg, and 1.2% for \u226525.0 mg.\n                    <\/jats:p>\n                    <jats:p>Incident CVD occurred in 13,426 (15.3%) people, including 6,013 atrial fibrillation, 7,727 heart failure, and 2,809 acute myocardial infarction events. One-year cumulative risks of all-cause CVD increased from 1.4% in periods of non-use to 8.9% for a daily prednisolone-equivalent dose of \u226525.0 mg. Five-year cumulative risks increased from 7.1% to 28.0%, respectively. Compared to periods of non-glucocorticoid use, those with &lt;5.0 mg daily prednisolone-equivalent dose had increased all-cause CVD risk (HR = 1.74; 95% confidence interval [CI] 1.64\u20131.84; range 1.52 for polymyalgia rheumatica and\/or giant cell arteritis to 2.82 for systemic lupus erythematosus). Increased dose-dependent risk ratios were found regardless of disease activity level and for all type-specific CVDs. HRs for type-specific CVDs and &lt;5.0-mg daily dose use were: 1.69 (95% CI 1.54\u20131.85) for atrial fibrillation, 1.75 (95% CI 1.56\u20131.97) for heart failure, 1.76 (95% CI 1.51\u20132.05) for acute myocardial infarction, 1.78 (95% CI 1.53\u20132.07) for peripheral arterial disease, 1.32 (95% CI 1.15\u20131.50) for cerebrovascular disease, and 1.93 (95% CI 1.47\u20132.53) for abdominal aortic aneurysm.<\/jats:p>\n                    <jats:p>The lack of hospital medication records and drug adherence data might have led to underestimation of the dose prescribed when specialists provided care and overestimation of the dose taken during periods of low disease activity. The resulting dose misclassification in some patients is likely to have reduced the size of dose\u2013response estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we observed an increased risk of CVDs associated with glucocorticoid dose intake even at lower doses (&lt;5 mg) in 6 immune-mediated diseases. These results highlight the importance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003432","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T13:29:41Z","timestamp":1607002181000},"page":"e1003432","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":271,"title":["Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-1028","authenticated-orcid":true,"given":"Mar","family":"Pujades-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-624X","authenticated-orcid":true,"given":"Ann W.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-3600","authenticated-orcid":true,"given":"Richard M.","family":"Cubbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-599X","authenticated-orcid":true,"given":"Jianhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"2","key":"pmed.1003432.ref001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/art.23352","article-title":"Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?","volume":"59","author":"I Karp","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"pmed.1003432.ref002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"PC Souverein","year":"2004","journal-title":"Heart"},{"issue":"10","key":"pmed.1003432.ref003","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"L Wei","year":"2004","journal-title":"Ann Intern Med"},{"issue":"10","key":"pmed.1003432.ref004","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjmed.2006.02.031","article-title":"Metabolic syndrome and risk of cardiovascular disease: a meta-analysis","volume":"119","author":"A Galassi","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"pmed.1003432.ref005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"AS Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"pmed.1003432.ref006","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"S Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"pmed.1003432.ref007","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/archinternmed.2009.297","article-title":"Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study","volume":"169","author":"CF Christiansen","year":"2009","journal-title":"Arch Intern Med"},{"issue":"3","key":"pmed.1003432.ref008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000168087","article-title":"Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy","volume":"10","author":"S Fujimoto","year":"1990","journal-title":"Am J Nephrol"},{"issue":"3","key":"pmed.1003432.ref009","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrcardio.2010.2","article-title":"Are glucocorticoids a treatment or a risk factor?","volume":"7","author":"M Rienstra","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"pmed.1003432.ref010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071890","article-title":"Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases","volume":"19","author":"A Arida","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pmed.1003432.ref011","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/art.22418","article-title":"Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study","volume":"56","author":"JM Davis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pmed.1003432.ref012","doi-asserted-by":"crossref","first-page":"e87965","DOI":"10.1371\/journal.pone.0087965","article-title":"Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study.","volume":"9","author":"AM van Sijl","year":"2014","journal-title":"PLoS ONE"},{"issue":"9","key":"pmed.1003432.ref013","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archinte.166.9.1016","article-title":"Corticosteroids and the risk of atrial fibrillation","volume":"166","author":"CS van der Hooft","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9","key":"pmed.1003432.ref014","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","article-title":"The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis","volume":"58","author":"F Wolfe","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pmed.1003432.ref015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","article-title":"Use of oral corticosteroids and the risk of acute myocardial infarction","volume":"192","author":"C Varas-Lorenzo","year":"2007","journal-title":"Atherosclerosis"},{"issue":"8","key":"pmed.1003432.ref016","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.23935","article-title":"Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study","volume":"59","author":"Z Nadareishvili","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pmed.1003432.ref017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2010.02.040","article-title":"Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review","volume":"78","author":"A Ruyssen-Witrand","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"3","key":"pmed.1003432.ref018","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data Resource Profile: Clinical Practice Research Datalink (CPRD).","volume":"44","author":"E Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"5","key":"pmed.1003432.ref019","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","article-title":"Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis","volume":"68","author":"M Movahedi","year":"2016","journal-title":"Arthritis & rheumatology"},{"issue":"25","key":"pmed.1003432.ref020","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1503\/cmaj.190178","article-title":"Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England","volume":"191","author":"J Wu","year":"2019","journal-title":"CMAJ"},{"issue":"12","key":"pmed.1003432.ref021","first-page":"E295","article-title":"Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study","volume":"192","author":"TF Mebrahtu","journal-title":"CMAJ. 2020"},{"issue":"1","key":"pmed.1003432.ref022","article-title":"Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis","volume":"8","author":"J Wu","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6732","key":"pmed.1003432.ref023","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","article-title":"The Read clinical classification","volume":"300","author":"J. Chisholm","year":"1990","journal-title":"BMJ"},{"key":"pmed.1003432.ref024","doi-asserted-by":"crossref","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"E Herrett","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"pmed.1003432.ref025","doi-asserted-by":"crossref","first-page":"e0151245","DOI":"10.1371\/journal.pone.0151245","article-title":"Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England","volume":"11","author":"M Pujades-Rodriguez","year":"2016","journal-title":"PLoS ONE."},{"issue":"8","key":"pmed.1003432.ref026","doi-asserted-by":"crossref","first-page":"e104671","DOI":"10.1371\/journal.pone.0104671","article-title":"Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention","volume":"9","author":"M Pujades-Rodriguez","year":"2014","journal-title":"PLoS ONE."},{"issue":"9932","key":"pmed.1003432.ref027","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"E Rapsomaniki","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"pmed.1003432.ref028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"AD Shah","year":"2015","journal-title":"The lancet Diabetes & endocrinology"},{"key":"pmed.1003432.ref029","volume-title":"The English indices of deprivation, 2007: Technical Report","author":"M Noble","year":"2008"},{"key":"pmed.1003432.ref030","author":"D. Hain","year":"2007","journal-title":"Index of Multiple Deprivation Score"},{"key":"pmed.1003432.ref031","doi-asserted-by":"crossref","DOI":"10.1002\/9780470870709","volume-title":"Competing Risks: A Practical Perspective","author":"M. Pintilie","year":"2006"},{"key":"pmed.1003432.ref032","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"J Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"pmed.1003432.ref033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2015-308514","article-title":"Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases","volume":"102","author":"M Pujades-Rodriguez","year":"2016","journal-title":"Heart"},{"issue":"1","key":"pmed.1003432.ref034","doi-asserted-by":"crossref","first-page":"e0191214","DOI":"10.1371\/journal.pone.0191214","article-title":"Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records","volume":"13","author":"M Pujades-Rodriguez","year":"2018","journal-title":"PLoS ONE"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:52:22Z","timestamp":1697280742000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003432"}},"subtitle":[],"editor":[{"given":"Kazem","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003432","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.11.20034157","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}